Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer
NCT05772377Phase 2
Key facts
- Status
- Unknown
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Sponsor
- Jiangsu Provincial People's Hospital
- Modality
- Small Molecules
- Drugs
- anlotinib
- Conditions
- Cervical Cancer (CC)
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Cervical Cancer (CC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Recurrence-Free Survival at 1 year. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Anlotinib+TP then CCRT+Anlotinib
Induction with Anlotinib+TP followed by CCRT with Anlotinib+Cisplatin and consolidation
03
Who it enrols
Patients with pathologically confirmed locally advanced cervical cancer (FIGO IB3, IIA2-IVA) who are treatment-naïve.
04
Endpoints
Primary
Recurrence-Free Survival
Secondary
Tumor Marker Complete Response Rate
Progression-Free Survival
Objective Response Rate
Overall Survival
Adverse Events
Beyond the preview
Go deeper on NCT05772377.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05772377.